FDA, Capricor battle over DMD cell therapy's efficacy at adcomm

AdComNegative

AI Analysis

Summary

Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy faced an FDA advisory committee meeting where the agency and company presented conflicting interpretations of the clinical efficacy data supporting the potential treatment.

Clinical Trial Data

Outcome Details

FDA and Capricor offered sharply opposed interpretations of clinical data at advisory committee meeting

Importance:7/10

Sentiment:

-0.30

cell therapyDMDrare diseaseFDA advisory committeeefficacy dispute

Related Companies

$CAPR

Read the original article

Published by Endpoints News on July 29, 2026 6:11 PM

Read Original